Acetoxymethylketobemidone (commonly referred to as O-AMKD) is a designer opioid substance that shares a kinship with ketobemidone, offering a potency level similar to morphine. Its presence came to light in Germany in October 2020, marking its initial identification.
|Chemical and physical data|
|Molar mass||275.348 g·mol−1|
1. What is Acetoxymethylketobemidone (O-AMKD)?
Acetoxymethylketobemidone, often known as O-AMKD, is a synthetic opioid substance that is chemically related to ketobemidone. It shares a similar potency to morphine.
2. How is Acetoxymethylketobemidone used?
Acetoxymethylketobemidone is typically consumed in various forms, including as a powder or crystalline substance. It can be ingested orally, inhaled nasally, or administered through intravenous injection. However, its use is associated with significant risks and is often illegal in many regions.
3. What are the effects of Acetoxymethylketobemidone?
The effects of Acetoxymethylketobemidone are similar to those of opioids like morphine. Users may experience pain relief, euphoria, and relaxation. However, this substance also poses serious risks, including the potential for life-threatening respiratory depression.
4. Is Acetoxymethylketobemidone legal?
The legal status of Acetoxymethylketobemidone varies depending on the jurisdiction. In many places, it is classified as a controlled substance, making its production, distribution, and possession illegal. It is crucial to be aware of local laws and regulations regarding this substance.
5. Is Acetoxymethylketobemidone safe to use?
No, Acetoxymethylketobemidone is not considered safe for recreational or medicinal use. It is a potent opioid and carries a high risk of overdose and severe adverse effects, including fatalities. The use of this substance is strongly discouraged.
6. Can Acetoxymethylketobemidone be addictive?
Yes, like other opioids, Acetoxymethylketobemidone has the potential for addiction and physical dependence. Its use can lead to the development of tolerance and withdrawal symptoms upon cessation.
7. What are the potential dangers associated with Acetoxymethylketobemidone?
The dangers linked to Acetoxymethylketobemidone include the risk of overdose and respiratory depression, which can be life-threatening. Additionally, this substance may contain impurities or be adulterated with other harmful substances, further increasing the dangers of its consumption.
8. Are there any medical uses for Acetoxymethylketobemidone?
No, Acetoxymethylketobemidone is not approved for any medical or therapeutic purposes. It is primarily intended for research purposes within a controlled laboratory setting.
9. Where can I seek help for Acetoxymethylketobemidone-related issues?
If you or someone you know is struggling with substance abuse or addiction related to Acetoxymethylketobemidone or any other opioid, it is essential to seek professional help. Reach out to local addiction treatment centers, medical professionals, or addiction support services for guidance and support.
10. How can Acetoxymethylketobemidone-related harm be prevented?
Preventing harm associated with Acetoxymethylketobemidone involves education, awareness, and strict adherence to legal regulations. Avoid using this substance, and encourage others to do the same. Promote responsible drug use and seek assistance for addiction or substance abuse issues promptly.
- Insights from the European Monitoring Center for Drugs and Drug Addiction In December 2020, the European Monitoring Center for Drugs and Drug Addiction unveiled a comprehensive report titled “New Psychoactive Substances: Global Markets, Glocal Threats, and the COVID-19 Pandemic.” This enlightening document, available in PDF format, provides critical updates through the EU Early Warning System, with its headquarters in Luxembourg. The report’s DOI is 10.2810/921262, and it carries ISBN 9789294975584.
- Novel Synthetic Opioids: A Darknet Market Exploration In August 2021, Lamy FR, Daniulaityte R, Barratt MJ, Lokala U, Sheth A, and Carlson RG delved into the world of non-fentanyl novel synthetic opioids. Their research, published in “Drug and Alcohol Dependence,” explored the presence of substances like “Etazene,” which was marketed as “safer than heroin and fentanyl.” This study sheds light on the listings of these novel opioids within a darknet market. The publication’s DOI is 10.1016/j.drugalcdep.2021.108790, and it is associated with PMID 34091156. Additionally, it is identified by S2CID 235362241.